[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xian-Janssen Pharmaceutical Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100616188",false,"NCT07302360","A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis","Guselkumab Real-world Effectiveness Among Bio-NaÏve Patients With Moderate-to-severe Ulcerative Colitis in China: A Multicenter, Non-interventional, Prospective Study","GENIUS","Inclusion criteria:\n\n* Has a confirmed diagnosis of moderately to severely active UC, defined as: a) baseline modified Mayo score of 4 to 9; b) screening endoscopy with Mayo endoscopic subscore (MES) greater than or equal to (\\>=) 2; c) Mayo rectal bleeding subscore (RBS) \\>= 1 at baseline\n* Eligible for advanced treatment and initiate guselkumab therapy per participating physician decision in accordance with product package insert\n* Have no prior exposure to advanced therapies (bio-naive), such as tumor necrosis factor (TNF)-alpha antagonists, anti-integrin agents, anti-interleukin (IL) agents, sphingosine-1-phosphate receptor modulators, janus kinase (JAK) inhibitors or their corresponding generics and biosimilars, per participating physician assessment\n* Participant (and\u002For their legally-acceptable representative where applicable) must sign an informed consent form (ICF) allowing source data verification in accordance with local requirements\n\nExclusion criteria:\n\n* Acute severe UC or infectious colitis or other conditions when patients is likely to require a colectomy\n* Contraindicated to guselkumab per the label\n* Currently enrolled in or plan to participate in any other clinical trials from signing informed consent to the final dose administration of guselkumab\n* Participants who will be receiving guselkumab therapy combined with a second advanced therapy\n* Participants with a history of colectomy and\u002For pouch","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess the measurable changes in health, function, or quality of life (clinical outcomes) after receiving guselkumab in real-world clinical practice amongst Chinese participants with ulcerative colitis (UC; a long-term disease of the large intestine in which the lining of the colon \\[part of large intestine\\] becomes inflamed and develops tiny open ulcers), who have not received biologic therapy (a medicine made from living organisms or their components) previously.",[24],"Colitis, Ulcerative","RECRUITING","2026-06-04",{"date":28,"type":29},"2026-06-05","ACTUAL",{"date":31,"type":29},"2025-12-11",{"date":33,"type":20},"2028-06-30",{"name":35,"class":36},"Xian-Janssen Pharmaceutical Ltd.","INDUSTRY",9,{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":58},"100616783","NCT07310095","A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab","Inclusion Criteria:\n\n* Has a confirmed diagnosis of Crohn's disease (CD)\n* Diagnosed with active CD, as defined by baseline Crohn's Disease Activity Index (CDAI) score greater than or equal to (\\>=) 220 and either mean daily stool frequency (SF) count \\>= 4 or mean daily abdominal pain (AP) score \\>=2\n* Participants had received at least two doses of ustekinumab (UST) (induction of 6 milligram \\[mg\\]\u002Fkilogram \\[kg\\] intravenous \\[IV\\] followed by 90 mg subcutaneous \\[SC\\] at week 8) as the instruction manual\n* Initially responded to UST induction therapy and then lose response to UST\n* During the screening period, participants are receiving UST treatment as the first line biologic or second line biologic\n\nExclusion Criteria:\n\n* Have responded well to treatment with UST in a dosing regime that is not in line with to the approved recommended dosing (for example, multiple intravenous induction) experienced optimized treatment with UST(not as instruction manual)\n* Participants with CD requiring urgent surgical or endoscopic intervention, or requiring elective surgery within 2 months\n* Is currently enrolled in an interventional clinical study\n* Complications of CD, such as symptomatic strictures or stenoses, short gut syndrome\n* Have a current or be suspected to have an abscess",{"count":45,"type":20},78,"INTERVENTIONAL",[48],"PHASE4","The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.",[51],"Crohn Disease",{"date":28,"type":29},{"date":54,"type":29},"2025-12-30",{"date":56,"type":20},"2027-11-15",{"name":35,"class":36},5,""]